Physician profile
Michael Bobrow
NPI 1467416768
$3,339.82
in general payments reported to CMS, 2019-2025
25 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $58.54 · 2021: $67.19 · 2022: $556 · 2023: $626 · 2024: $963 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,873.71 |
| Education | $131.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.87 | 2019-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $391.11 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $371.54 | 2019-2024 | |
| Janssen Biotech, INC. | $352.81 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $312.60 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $181.82 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $169.44 | 2019-2024 | Dupixent |
| Pfizer INC. | $149.88 | 2019-2025 | |
| Galderma Laboratories, L.P. | $129.30 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Dermavant Sciences, INC. | $113.16 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $112.70 | 2022-2025 | Sotyktu |
| Amgen INC. | $101.88 | 2024-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Arcutis Biotherapeutics, INC. | $58.39 | 2023-2024 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $47.52 | 2019 | |
| Celgene Corporation | $43.75 | 2019 | |
| Genentech USA, INC. | $40.80 | 2019-2025 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.94 | 2019 | |
| Sun Pharmaceutical Industries INC. | $26.11 | 2024 | |
| Leo Pharma INC. | $22.95 | 2020 | |
| Verrica Pharmaceuticals INC. | $21.39 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.44 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $14.47 | 2019 | |
| Organon LLC | $11.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bobrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.